Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as α7 nicotinic acetylcholine receptor agonists

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 24, 2006, Pages 8219-8248

  Walker, Daniel P ^a   Wishka, Donn G ^a   Piotrowski, David W ^a   Jia, Shaojuan ^a   Reitz, Steven C ^a   Yates, Karen M ^a   Myers, Jason K ^a   Vetman, Tatiana N ^a   Margolis, Brandon J ^a   Jacobsen, E Jon ^a   Acker, Brad A ^a   Groppi, Vincent E ^a   Wolfe, Mark L ^a   Thornburgh, Bruce A ^a   Tinholt, Paula M ^a   Cortes Burgos, Luz A ^a   Walters, Rodney R ^a   Hester, Matthew R ^a   Seest, Eric P ^a   Dolak, Lester A ^a   Han, Fusen ^a   Olson, Barbara A ^a   Fitzgerald, Laura ^a   Staton, Brian A ^a   Raub, Thomas J ^a   Hajos, Mihaly ^a   Hoffmann, William E ^a   Li, Kai S ^a   Higdon, Nicole R ^a   Wall, Theron M ^a   Hurst, Raymond S ^a   Wong, Erik H F ^a   Rogers, Bruce N ^a   more..

^a PFIZER INC   (United States)

Author keywords

7; nAChR; Nicotinic; PHA 543613

Indexed keywords

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST; BENZIMIDAZOLE; BENZODIOXANE; BENZODIOZOLE; BENZOTHIAZOLE; DIOXOLOPYRIDINE; FUROPYRIDINE; INDAZOLE DERIVATIVE; INDOLIZINE DERIVATIVE; N [1 AZABICYCLO[2.2.1]HEPT 3 YL]FURO[2,3 ]PYRIDINE 5 CARBOXAMIDE FUMARATE; N [1 AZABICYCLO[2.2.2]OCT 3 YL] 1,3 BENZODIOXOLE 5 CARBOXAMIDE 4 METHYLBENZENESULFONATE; N [1 AZABICYCLO[2.2.2]OCT 3 YL] 1H BENZIMIDAZOLE 5 CARBOXAMIDEBIS(4 ETHYLBENZENESULFONATE; N [1 AZABICYCLO[2.2.2]OCT 3 YL]IMIDAZO[1,2 A]PYRIDINE 7 CARBOXAMIDE; N [1 AZABICYCLO[2.2.2]OCT 3 YL]INDOLIZINE 6 CARBOXAMIDE DEXTRO TARTRATE; N [1 AZABICYCLO[2.2.2]OCT 3 YL]PYRROLO[1,2 A]PYRAZINE 3 CARBOXAMIDE DEXTRO TARTRATE; N [2 METHYL 1 AZABICYCLO[2.2.2]OCT 3YL]FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; N [2 METHYL1AZABICYCLO[2.2.2]OCT 3 YL]PYRROLO[1,2 C]PYRIMIDINE 3 CARBOXAMIDE; NICOTINIC AGENT; NICOTINIC RECEPTOR; PHA 543613; PNU 282987; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; RAT; RAT STRAIN; STRUCTURE ACTIVITY RELATION;

ANIMALS; BRAIN; BUNGAROTOXINS; CELLS, CULTURED; DRUG DESIGN; ELECTROPHYSIOLOGY; EVOKED POTENTIALS, AUDITORY; HIPPOCAMPUS; ION CHANNEL GATING; MOLECULAR STRUCTURE; MOTOR ACTIVITY; NEURONS; NICOTINIC AGONISTS; PATCH-CLAMP TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPSES;

EID: 33750532078     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.09.019     Document Type: Article

References (84)

1. For nAChR lead references see:. Picciotto M.R., Caldarone B.J., King S.L., and Zachariou V. Neuropsychopharmacology 22 (2000) 451
2. Dani J.A. Biol. Psychiatry 49 (2001) 166
3. In: Arneric S.P., and Brioni J.D. (Eds). Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities (1999), Wiley-Liss, New York
4. In: Clementi F., Fornasari D., and Gotti C. (Eds). Handbook of Experimental Pharmacology: Neuronal Nicotinic Receptors (2000), Springer, New York
5. Weiland S., Bertrand D., and Leonard S. Behav. Brain Res. 113 (2000) 43
6. Séguéla P., Wadiche J., Dineley-Miller K., Dani J.A., and Patrick J.W. J. Neurosci. 13 (1993) 596
7. Levin E.D., and Simon B.B. Psychopharmacology 138 (1998) 217
8. For reviews see:. Mazuriv A., Hauser T., and Miller C.H. Curr. Med. Chem. 13 (2006) 1567
9. Jensen A.A., Frolund B., Liljefors T., and Krogsgaard-Larsen P. J. Med. Chem. 48 (2005) 4705
10. Hashimoto K., Koike K., Shimizu E., and Iyo M. Curr. Med. Chem. 5 (2005) 171
11. Bunnelle W.H., Dart M.J., and Schrimpf M.R. Curr. Med. Chem. 4 (2004) 299
12. Romanelli M.N., and Gualtieri F. Med. Res. Rev. 23 (2003) 393
13. Astles P.C., Baker S.R., Boot J.R., Broad L.M., Dell C.P., and Keenan M. Curr. Drug Targets CNS Neuro. Disord. 1 (2002) 337
14. Schmitt J.D. Curr. Med. Chem. 7 (2000) 749 Also see references cited within these papers
15. Mullen G., Napier J., Balestra M., DeCory T., Hale G., Macor J., Mack R., Loch J., Wu E., Kover A., Verhoest P., Sampognaro A., Phillips E., Zhu Y., Murray R., Griffith R., Blosser J., Gurley D., Machulskis A., Zongrone J., Rosen A., and Gordon J. J. Med. Chem. 43 (2000) 4045
16. Macor, J.; Wu, E. PCT Int. Appl., WO9730998, Aug. 28, 1997.
17. Guendisch D., Andrae M., Munoz L., and Tilotta M.C. Bioorg. Med. Chem. 12 (2004) 4953
18. Bodnar A.L., Cortes-Burgos L.A., Cook K.K., Dinh D.M., Groppi V.E., Hajos M., Higdon N.R., Hoffmann W.E., Hurst R.S., Myers J.K., Rogers B.N., Wall T.M., Wolfe M.L., and Wong E. J. Med. Chem. 48 (2005) 905
19. Tatsumi R., Seio K., Fujio M., Katayama J., Horikawa T., Hashimoto K., and Tanaka H. Bioorg. Med. Chem. Lett. 14 (2004) 3781
20. Meyer E.M., Tay E.T., Papke R.L., Meyers C., Huang G.-L., and De Fiebre C.M. Brain Res. 768 (1997) 49
21. deFiebre C.M., Meyer E.M., Henry J.C., Muraskin S.I., Kem W.R., and Papke R.L. Mol. Pharmacol. 47 (1995) 164
22. Spande T.F., Garraffo H.M., Edwards M.W., Yeh H.J.C., Pannell L., and Daly J.W. J. Am. Chem. Soc. 114 (1992) 3475
23. Dukat M., Damaj M.I., Glassco W., Dumas D., May E.L., Martin B.R., and Glennon R.A. Med. Chem. Res. 4 (1994) 131
24. Bannon A.W., Decker M.W., Holladay M.W., Curzon P., Donnelly-Roberts D., Puttfarcken P.S., Bitner R.S., Diaz A., Dickenson A.H., Porsolt R.D., Williams M., and Arneric S.P. Science 279 (1998) 77
25. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., Sands S.B., Davis T.I., Lebel L.A., Fox C.B., Shrikhande A., Heym J.H., Schaeffer E., Rollema H., Lu Y., Mansbach R.S., Chambers L.K., Rovetti C.C., Schulz D.W., Tingley F.D., and O'Neill B.T. J. Med. Chem. 48 (2005) 3474
26. Wishka D.G., Walker D.P., Yates K.M., Reitz S.C., Jia S., Myers J.K., Olson K.L., Jacobsen E.J., Wolfe M.L., Groppi V.E., Hanchar A.J., Thornburgh B.A., Cortes-Burgos L.A., Wong E., Staton B.A., Raub T.J., Higdon N.R., Wall T.M., Hurst R.S., Walters R.R., Hoffmann W.E., Hajos M., Franklin S., Carey G., Gold L.H., Cook K.K., Sands S.B., Zhao S.X., Soglia J.R., Kalgutkar A.S., Arneric S.P., and Rogers B.N. J. Med. Chem. 49 (2006) 4425
27. Hajos M., Hurst R.S., Hoffmann W.E., Wall T.M., Higdon N.R., and Groppi V.E. J. Pharmacol. Exp. Ther. 312 (2005) 1213
28. See experimental section for full details on salt selection and on the preparation of the aryl carboxylic acids pieces.
29. 3 assay (data not shown). This paper only focuses on the biologically most relevant diastereomer of structures A, B, and C. {A figure is presented}
30. Nielsen A.T. J. Org. Chem. 31 (1966) 1053
31. Morgan Jr. T.K., Lis R., Marisca A.J., Argentieri T.M., Sullivan M.E., and Wong S.S. J. Med. Chem. 30 (1987) 2259
32. Compound 8 was prepared by coupling amine (+)-3 with 5-bromothiophenecarboxylic acid using HATU according to Scheme 2. Re-crystallization of 8 from ethyl acetate-methanol afforded crystals suitable for single crystal X-ray diffraction.
33. Barco A., Benetti S., Casolari A., Pollini G.P., and Spalluto G. Tetrahedron Lett. (1990) 3039
34. Barco A., Benetti S., and Spalluto G. J. Org. Chem. 57 (1992) 6279
35. O'Neill B.T., Thadeio P.F., Bundesmann M.W., Elder A.M., McLean S., and Bryce D.K. Tetrahedron 53 (1997) 11121
36. Single crystal X-ray diffraction of bromothienyl amide 16, prepared from (-)-14 according to Scheme 3, showed that it possesses the (3S,4R)-stereochemistry. Thus, the absolute stereochemistry of 15, which is derived from (+)-14, must be (3R, 4S).
37. Trudell M.L., and Zhang C. J. Org. Chem. 61 (1996) 7189
38. Singh S., and Basmadjian G.P. Tetrahedron Lett. (1997) 6829
39. Singh (Ref. 22b) reports a 3:1 ratio of exo:endo esters upon treating 17 with NaOMe/MeOH. We have obtained a 20:1 exo:endo ratio of the corresponding carboxylic acids by carefully quenching the reaction with water and adjusting the pH, which led to a selective fractional crystallization of the exo-isomer.
40. Compound 22 was prepared by coupling amine 21 with 5-bromothiophenecarboxylic acid using HATU according to Scheme 4. Re-crystallization of 22 from ether afforded crystals suitable for single crystal X-ray diffraction.
41. 3 chimera assay was previously established as predictive of native α7 nAChR activity, see: Refs. 7 and 13.
42. Eisele J.L., Bertrand S., Galzi J.L., Devillers-Thiery A., Changeux J.P., and Bertrand D. Nature 366 (1993) 479
43. Shaffer C.L., Gunduz M., Thornburgh B.A., and Fate G.D. Drug Metab. Dispos. 34 (2006) 1615-1623
44. Renaud, A.; Langlois, M.; Naylor, R. J.; Naylor, B. Eur. Pat. Appl. 311724, April 19, 1989.
45. Swain C.J., Baker R., Kneen C., Moseley J., Saunders J., Seward E.M., Stevenson G., Beer M., Stanton J., and Watling K. J. Med. Chem. 34 (1991) 140
46. Swain C.J., Baker R., Kneen C., Herbert R., Moseley J., Saunders J., Seward E.M., Stevenson G.I., Beer M., Stanton J., Watling K., and Ball R.G. J. Med. Chem. 35 (1992) 1019
47. Saunders J., MacLeod A.M., Merchant K., Showell G.A., Snow R.J., Street L.J., and Baker R. J. Chem. Soc., Chem. Commun. (1988) 1618
48. Ward J.S., Merritt L., Calligaro D.O., Bymaster F.P., Shannon H.E., Sawyer B.D., Mitch C.H., Deeter J.B., Peters S.C., Sheardown M.J., Olesen P.H., Swedberg M.D.B., and Sauerberg P. J. Med. Chem. 38 (1995) 3469
49. The measured log D values for azanorbornane analogs 9 are typically 0.5 log units lower than the corresponding quiuclidine analogs 1.
50. Briggs C.A., McKenna D.G., and Piattoni-Kaplan M. Neuropharmacology 34 (1995) 583
51. Holladay M.W., Dart M.J., and Lynch J.K. J. Med. Chem. 40 (1997) 4169
52. Daly J.W. Cell. Mol. Neurobiol. 25 (2005) 513
53. Maricq A.V., Peterson A.S., Brake A.J., Myers R.M., and Julius D. Science 254 (1991) 432
54. 3.
55. Compounds screened in Chan Test, hERG Comparitor Screen. See http://www.chantest.com for full information.
56. Viskin S. Lancet 354 (1999) 1625
57. Mitcheson J.S., Chen J., Lin M., Culberson C., and Sanguinetti M.C. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 12329
58. Estimated based on the compound's 27% fraction unbound (fu) and efficacious plasma concentration of 700 nM following a 1 mg/kg iv dose.
59. Smith B.J., Doran A.C., McLean S., Tingley F.D., O'Neill B.T., and Kajiji S.M. J. Pharm. Exp. Ther. 298 (2001) 125
60. Bakos E., Evers R., Szakacs G., Tusnady G.E., Welker E., Szabo K., De Haas M., Van Deemter L., Borst P., Varadi A., and Sarkadi B. J. Biol. Chem. 273 (1998) 32167
61. Indazole 1i was not assessed in the MDR or MBUA assays due to its poor oral bioavailability in rat.
62. Garberg P., Ball M., Borg N., Cecchelli R., Fenart L., Hurst R.D., Lindmark T., Mabondzo A., Nilsson J.E., Raub T.J., Stanimirovic D., Terasaki T., Oeberg J.-O., and Oesterberg T. Toxicol. In Vitro 19 (2005) 299
63. Stevens K.E., Meltzer J., and Rose G.M. Psychopharmacology 119 (1995) 163
64. Hajos M. Trend Pharmacol. Sci. 27 (2006) 391
65. Still W.C., Kahn M., and Mitra A. J. Org. Chem. 43 (1978) 2923
66. Carpino L.A. J. Am. Chem. Soc. 115 (1993) 4397
67. Downing S.V., Aguilar E., and Meyers A.I. J. Org. Chem. 64 (1999) 826
68. Langlois M., Soulier J.L., Mathe-Allainmat M., Gallais C., Bremont B., and Shen S. Bioorg. Med. Chem. Lett. 4 (1994) 945
69. Giardina G., Clarke G.D., Dondio G., Petrone G., Sbacchi M., and Vecchietti V. J. Med. Chem. 37 (1994) 3482
70. Meyer H. Monatsh. Chem. 26 (1905) 1323
71. Meyer H. Monatsh. Chem. 28 (1907) 36
72. Dallacker F.Z. Z. Naturforsch. B 34 (1979) 1729
73. Batt D.G., Petraitis J.J., Houghton G.C., Modi D.P., Cain G.A., Corjay M.H., Mousa S.A., Bouchard P.J., Forsythe M.S., Harlow P.P., Barbera F.A., Spitz S.M., Wexler R.R., and Jadhav P.K. J. Med. Chem. 43 (2000) 41
74. Minguez J.M., Vaquero J.J., Alvarez-Builla J., and Castano O. J. Org. Chem. 64 (1999) 7788
75. Dekhane M., Potier P., and Dodd R. Tetrahedron 49 (1993) 8139
76. Li Q., Woods K.W., Claiborne A., Gwaltney II S.L., Barr K.J., Liu G., Gehrke L., Credo R.B., Hui Y.H., Lee J., Warner R.B., Kovar P., Nukkala M.A., Zielinski N.A., Tahir S.K., Fitzgerald M., Kim K.M., Marsh K., Frost D., Ng S.-C., Rosenburg S., and Sham H.L. Bioorg. Med. Chem. Lett. 12 (2002) 465
77. Aristoff P.A., Harrison A.W., and Huber A.M. Tetrahedron Lett. (1984) 3955
78. Hirsch J.A., and Schwartzkopf G. J. Org. Chem. 38 (1973) 3534
79. Mochida K., Ono Y., Yamasaki M., Shiraki C., Hirata T., Sato K., and Okachi R. J. Antibiot. 40 (1987) 182
80. Grill C.M. J. Chromatogr. 796 (1998) 101
81. Grill C.M., and Miller J. J. Chromatogr. 827 (1998) 359
82. Brewer G.J. J. Neurosci. Methods 71 (1997) 143-155
83. Krause M., Hoffmann W.E., and Hajos M. Biol. Psychiatry 53 (2003) 244
84. Paxinos, G.; Watson, C. The Rat Brain in Stereotaxic Coordinates; Academic Press, Sydney, 1986.